Genotoxic Impurity Determination with LC-MS/MS

In pharmaceutical production and quality control, genotoxic impurities (GTIs) are trace-level contaminants (e.g., intermediates, by-products, degradation products) that have the potential to damage DNA, induce mutations, and increase long-term carcinogenic risks. For Active Pharmaceutical Ingredients (APIs) and excipients, strict control of genotoxic impurities is mandatory to ensure drug safety and compliance with global regulatory standards (ICH Q9, ICH M7, FDA, EMA, USP).

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) is the preferred method for genotoxic impurity determination due to its unparalleled ultra-trace detection capability, strong anti-matrix interference, and high specificity. Unlike other analytical techniques, LC-MS/MS excels in quantifying trace GTIs (down to ppb level) in high-concentration API and excipient matrices, avoiding false positive or false negative results. The use of MRM (Multiple Reaction Monitoring) mode ensures precise targeting of specific genotoxic impurities, even for structurally similar compounds (e.g., different nitrosamine derivatives). When coupled with professional sample pretreatment (SPE, LLE, derivatization), the technique eliminates matrix interference from non-target components, enhancing detection accuracy. Regulatory bodies such as the FDA, EMA, and NMPA mandate LC-MS/MS-based methods for GTI testing, ensuring compliance with global guidelines (ICH M7, USP, EP, ChP). The method's robustness, high-throughput capability, and regulatory compliance make it indispensable for quality control in API and excipient production and drug development.

Applications in Impurity Test

LC-MS/MS-based genotoxic impurity determination is suitable for a wide range of pharmaceutical materials, including:

• Active Pharmaceutical Ingredients (APIs) – Detection of Class 1, 2, and 3 genotoxic impurities from synthesis, reaction by-products, and degradation
• Excipients (starches, cellulose, sugars, surfactants, preservatives, etc.) – Screening for residual GTIs from production and storage

PharmaAnalytica's Technology Platform

PharmaAnalytica's LC-MS/MS-Based GTI Test Service

Regulatory-Compliant Method Development & Validation

We design and validate LC-MS/MS methods in full alignment with ICH Q2(R1), ICH M7, USP, EP, and ChP guidelines, including method suitability for diverse API and excipient matrices, customized calibration for trace GTIs, and stability-indicating protocols to track GTI levels under different storage conditions (temperature, humidity, light).

Comprehensive GTI Detection & Analysis

We provide targeted detection of known GTIs based on API synthetic routes, screening and identification of unknown potential GTIs in novel APIs, and evaluation of GTI formation from excipient production and API-excipient interactions. Our high-throughput testing capability ensures efficient delivery of results for large-batch samples.

Comprehensive Data Reporting & Interpretation

We provide detailed analytical reports with complete chromatograms, peak integration results, and quantitative data, along with expert interpretation to help clients understand compliance status, GTI sources, and potential risks, ensuring seamless integration into regulatory documentation.

End-to-End Support

Beyond testing, we assist with GTI risk assessment per ICH M7 classification, justification reports for impurity limit waivers, and deficiency response packages for FDA/EMA/NMPA inquiries, supporting drug registration and market access.

PharmaAnalytica's Genotoxic Impurity Determination with LC-MS/MS service combines cutting-edge pure domestic LC-MS/MS technologies, regulatory expertise, and customized solutions to deliver reliable results. We specialize in analyzing complex API and excipient matrices, offering tailored solutions from method development to regulatory submission support. Our commitment to precision, rapid turnaround times, and comprehensive data interpretation ensures your products meet ICH, USP, EP, and NMPA standards efficiently.